Paysign, Inc. (PAYS)

NASDAQ: PAYS · Real-Time Price · USD
5.62
-0.17 (-2.94%)
At close: May 15, 2026, 4:00 PM EDT
5.55
-0.07 (-1.25%)
After-hours: May 15, 2026, 5:48 PM EDT
Market Cap314.19M +154.2%
Revenue (ttm)91.47M +43.4%
Net Income10.40M +70.8%
EPS0.17 +56.6%
Shares Out 55.91M
PE Ratio32.75
Forward PE24.43
Dividendn/a
Ex-Dividend Daten/a
Volume494,620
Open5.80
Previous Close5.79
Day's Range5.44 - 5.89
52-Week Range3.08 - 8.88
Beta0.72
AnalystsStrong Buy
Price Target10.00 (+77.94%)
Earnings DateMay 12, 2026

About PAYS

Paysign, Inc. provides prepaid card programs, patient affordability offerings, digital banking, life science software technology solutions, and integrated payment processing services for businesses, consumers, and government institutions in the United States. The company offers solutions for corporate rewards, prepaid gift cards, general-purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts a... [Read more]

Sector Technology
IPO Date Apr 2, 1998
Employees 226
Stock Exchange NASDAQ
Ticker Symbol PAYS
Full Company Profile

Financial Performance

In 2025, Paysign's revenue was $82.03 million, an increase of 40.50% compared to the previous year's $58.38 million. Earnings were $7.55 million, an increase of 97.90%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for PAYS stock is "Strong Buy." The 12-month stock price target is $10.0, which is an increase of 77.94% from the latest price.

Price Target
$10.0
(77.94% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Paysign reports Q1 EPS 9c vs. 5c last year

Reports Q1 revenue $28.04M vs. $18.6M last year. “Paysign (PAYS) delivered a strong start to 2026, with exceptional top- and bottom-line results that are consistent with our strategic direction and…

3 days ago - TheFly

Paysign sees FY26 EPS 21c-26c

Sees revenue $106.5M-$110.5M. Sees adjusted EBITDA $30M-$33M. “Our first quarter results exceeded guidance across every line of the income statement,” commented Jeff Baker, Chief Financial Officer of ...

3 days ago - TheFly

Paysign sees Q2 EPS 6c-7c

Sees Q2 revenue $26.2M-$26.7M. Sees Q2 adjusted EBITDA $7.7M-$8.5M.

3 days ago - TheFly

Paysign Earnings Call Transcript: Q1 2026

Record Q1 results with revenue up 50.8% and net income up 110% year-over-year, driven by strong growth in patient affordability and plasma segments. Guidance raised for 2026, with robust pipelines and no expected impact from plasma center closures.

4 days ago - Transcripts

Paysign's Patient Affordability Drives 51% Revenue Growth and Significant Margin Expansion for First Quarter 2026

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign's Patient Affordability Drives 51% Revenue Growth and Significant Margin Expansion for First Quarter 2026.

4 days ago - Business Wire

Paysign management to meet with Barrington

Meeting to be held in Minneapolis on May 18 hosted by Barrington.

5 days ago - TheFly

Paysign to Host First Quarter 2026 Earnings Call

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign to Host First Quarter 2026 Earnings Call.

4 weeks ago - Business Wire

Paysign price target raised to $11 from $10 at Lake Street

Lake Street analyst Jacob Stephan raised the firm’s price target on Paysign (PAYS) to $11 from $10 and keeps a Buy rating on the shares. The firm, which is raising…

7 weeks ago - TheFly

Paysign Earnings Call Transcript: Q4 2025

Revenue grew 40.5% to $82M in 2025, with net income up 98% and strong margin expansion. Patient Affordability revenue surged 168%, and 2026 guidance calls for 30–35% growth, driven by both plasma and pharma segments.

7 weeks ago - Transcripts

Paysign reports Q4 adjusted EPS 9c, consensus 3c

Reports Q4 revenue $22.76M, consensus $21.55M. “2025 was a standout year for Paysign (PAYS), delivering record top- and bottom-line results,” commented Mark Newcomer, President and CEO of Paysign. “We...

7 weeks ago - TheFly

Paysign sees Q1 adjusted EPS 15c-16c, consensus 7c

Sees Q1 revenue $27M-$27.5M, consensus $23.83M.

7 weeks ago - TheFly

Paysign sees FY26 adjusted EPS 49c-53c, consensus 24c

Sees FY26 revenue $106.5M-$110.5M, consensus $97.48M. v

7 weeks ago - TheFly

Paysign sees FY26 adjusted EPS 49c-53c, consensus 24c

Sees FY26 revenue $106.5M-$110.5M, consensus $97.48M.

7 weeks ago - TheFly

Paysign, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results; Patient Affordability Drives 40% Revenue Growth and Significant Margin Expansion

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results.

7 weeks ago - Business Wire

Paysign to Host Fourth Quarter and Full Year 2025 Earnings Call

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign to Host Fourth Quarter and Full Year 2025 Earnings Call.

2 months ago - Business Wire

Paysign, Inc. to Present at the Oppenheimer 11th Annual Emerging Growth Conference

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. to Present at the Oppenheimer 11th Annual Emerging Growth Conference.

4 months ago - Business Wire

Paysign, Inc. Announces 2025 Performance Analysis of Patient Affordability Solutions

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. Announces 2025 Performance Analysis of Patient Affordability Solutions.

4 months ago - Business Wire

Paysign Transcript: 17th Annual Southwest IDEAS Conference

Leadership with deep payments and banking expertise drives growth in patient affordability and plasma payment sectors. Proprietary technology and high client retention fuel strong financial performance, with revenue and margins rising year-over-year.

6 months ago - Transcripts

Paysign, Inc. to Present at the 17th Annual Southwest IDEAS Investor Conference

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. to Present at the 17th Annual Southwest IDEAS Investor Conference.

6 months ago - Business Wire

Paysign Earnings Call Transcript: Q3 2025

Q3 2025 saw record revenue and profit growth, led by a 142% surge in patient affordability revenue and continued expansion in plasma. Guidance for 2025 was raised, with strong margin improvements and robust cash flow, despite plasma industry oversupply and regulatory delays for new tech platforms.

6 months ago - Transcripts

Paysign reports Q3 adjusted EPS 8c, two estimates 4c

Reports Q3 revenue $21.6M, consensus $19.92M. “Q3 2025 proved once again to be a record-breaking quarter for Paysign (PAYS),” said Mark Newcomer, President and CEO. “Our revenue soared to $21.6…

6 months ago - TheFly

Paysign sees FY25 adjusted EPS 32c-34c, consensus 17c

Raises FY25 revenue view to $80.5M-$81.5M from $76.5M-$78.5M, consensus $77.53M.

6 months ago - TheFly

Paysign, Inc. Reports Third Quarter 2025 Financial Results

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. Reports Third Quarter 2025 Financial Results.

6 months ago - Business Wire

Paysign to Host Third Quarter 2025 Earnings Call

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign to Host Third Quarter 2025 Earnings Call.

7 months ago - Business Wire

Paysign, Inc. Appoints Jose Garcia as Executive Vice President, Life Science Solutions

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. Appoints Jose Garcia as Executive Vice President, Life Science Solutions.

8 months ago - Business Wire